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Ee = 88% 
[a]D = - 17.7 (c 1, CHCl3, 88% ee from HPLC) 
Source of chirality: (Sa)-Binap 
 

















Ee = 30% 
[a]D = - 12.8 (c 1, CHCl3, 30% ee from HPLC) 
Source of chirality: (Sa)-Binap 
 
















Ee = 90% 
[a]D = - 23.8 (c 1, CHCl3, 90% ee from HPLC) 
Source of chirality: (Sa)-Binap 
 







































Diethyl (1S,3R,3aS,6aR)-1-benzyl-5-(4-bromophenyl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1,3-dicarboxylate  
 
 
Ee = 92% 
[a]D = - 32.6 (c 1, CHCl3, 92% ee from HPLC) 
Source of chirality: (Sa)-Binap 













Diethyl (1S,3R,3aS,6aR)-1-benzyl-4,6-dioxo-5-phenyl octahydropyrrolo[3,4-c]pyrrole-1,3-dicarboxylate 
 
 
Ee = 90% 
[a]D = - 28.0 (c 1, CHCl3, 90% ee from HPLC) 
Source of chirality: (Sa)-Binap  
















Ee = 80% 
[a]D = - 36.9 (c 1, CHCl3, 80% ee from HPLC) 
Source of chirality: (Sa)-Binap 
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Abstract:  The enantioselective binap-silver catalyzed multicomponent 1,3-dipolar cycloaddition 
using ethyl glyoxylate, phenylalanine ethyl ester and maleimides is described. The employment of 
the basic silver carbonate allows the reaction in the absence of an extra base giving high yields and 
ee. In addition, a low-level calculations regarding the importance of the benzyl substituent at the α-
position of the amino ester justify the expected absolute configuration of final cycloadducts and the 
observed high enantiodiscrimination. 
 




Since Huisgen´s seminal work1 1,3-dipolar cycloadditions (1,3-DC) emerged as a potent and 
useful tool in organic synthesis.2 Modern chemistry focused on asymmetric synthesis increased the 
interest of the organic chemists by these transformations in which it is possible to achieve just in 
one step up to four stereogenic centres in multiple series of heterocycles or cyclopentanes. 
Concerning the reaction involving azomethine ylides and alkenes, very efficient chiral 
organocatalyst- or chiral Lewis acid-mediated processes have been published since 2002.3 In all of 
them, the reaction occurred starting from the freshly prepared imino ester which is the direct 
precursor of the azomethine ylide. However, it is noteworthy that the multicomponent4 version of 
this 1,3-DC5 is not frequently found in the literature. A few examples have been recently recorded 
in cycloadditions promoted by organocatalysts, for example, chiral prolinol derivatives,6 chiral 
phosphoric acids,7 chiral thioureas,8 and chiral squaramides.9 However, the multicomponent 
asymmetric 1,3-DC of azomethine ylides employing chiral metal complexes has been seldom 
achieved.10  
In previous contributions, our group pioneered the development of these multicomponent 
1,3-DCs by using binap·AgSbF6 complex in the transformation involving imino esters and 
maleimides or 1,2-bis(phenylsulfonyl)ethylene.11 We have recently reported that ethyl glyoxylate 1 
can be used as aldehyde in a multicomponent diastereoselective 1,3-DC with α-amino esters 2 
(derived from glycine, alanine, phenylalanine, and phenylglycine) and different dipolarophiles 3 
(Scheme 1).12 Microwave-assisted heating processes gave better results than conventional heating 
ones, affording endo-cycloadducts as major stereoisomers with a 2,5-cis-relative arrangement 
through the W-shaped dipole. We describe here the binap·silver(I) catalyzed enantioselective 
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2. Results and discussion 
 
Privileged chiral ligands13 selected for this survey, such as phosphoramidite 5 and binap 6, 
were successfully employed in precedent multicomponent or two-component1,3-DC14 reported by 
our group (Figure 1). The starting model reaction for the study of this enantioselective 1,3-DC 
process involved ethyl glyoxylate 1, amino ester hydrochloride 2 and N-methylmaleimide 3a 
(NMM) using 5 mol% of both chiral ligand and silver trifluoroacetate (Agtfa) in toluene at room 










(Sa,R,R)-5 (S)-Binap 6  
 
Figure 1. Chiral privileged ligands employed in this work. 
 
 
Preliminary results demonstrated that phosphoramidite ligand 5 was not appropriate for this 
transformation (Table 1, entries 1, 3, 5, 7 and 9). Glycine, alanine, and phenylglycine derivatives 2 
gave good yields but low enantioselectivities (Table 1, entries 2, 4, and 8). Only phenylalanine ethyl 
ester hydrochloride 2c·HCl reacted in the presence of binap affording the corresponding 
cycloadduct 4 with a modest 30% ee (Table 1, entry 6) in 10 h. Low enantioselection was again 
detected in the presence of the chiral phosphoramidite 5·Agtfa complex when the free 
phenylalanine ethyl ester was employed, but the enantioselection was improved in the binap 
6·AgTfa-catalyzed process to 70% ee (Table 1, entries 9 and 10). In this last example exclusively 
one 2,5-cis-endo-diastereoisomer 4ca was identified.  
 



























Table 1. Study of the reaction conditions. 
Ent. 2·HCl R1 R2 Ligand Product 4 Conv.a eeb 
1 2a·HCl Et H 5 4aa 100 0 
2 2a·HCl Et H 6 4aa 100 0 
3 2b·HCl Me Me 5 4ba 20 0 
4 2b·HCl Me Me 6 4ba 60 6 
5 2c·HCl Et Bn 5 4ca 90 0 
6 2c·HCl Et Bn 6 4ca 95 30 
7 2d·HCl Me  Ph 5 4da 67 0 
8 2d·HCl Me Ph 6 4da 85 7 
9 2cc Et Bn 5 4ca 100 15 
10 2cc Et Bn 6 4ca 100 70 
a Determined by 1H NMR of the crude reaction mixture. 10 h Reaction time. 
b Determined by HPLC using chiral columns. 
c Free amino ester was used. 
 
 
The 1,3-DC of 1 with phenylalanine ethyl ester (2c) and NMM (3a) was performed in the 
presence of binap (5 mol%) and different silver salts (5 mol%) in toluene (Scheme 2 and Figure 2). 
The modification of the stoichiometry binap:silver cation or the loading of the catalyst did not 
improve the previous results (Table 1, entry 10). The analysis of the solvent effect was also 
evaluated (toluene, THF, diethyl ether, dichloromethane, water, methanol, and acetonitrile were 
tested) and, as conclusion, toluene was the most appropriate giving pure crude reaction product 4ca. 
Due to the formation of three different silver aggregates of binap·AgOTf at different 
temperatures,15 we decided to carry out a study at different temperatures (Figure 2). At room 
temperature the reaction took place in 10 h and AgOAc gave the highest 79% ee. When the reaction 
was performed at -20 ºC Agtfa gave the highest 90% ee, which could also obtained employing 
Ag2CO3 at -10 ºC, being necessary 24 h for the reaction completion in both examples.   
 
 





















Scheme 3. Optimization reaction of (S)-binap 6·silver salt-temperature-solvent parameter in the 




Figure 2. Effect of (S)-binap 6·silver salt-temperature-toluene in the enantiomeric excess of 
cycloadduct 4ca.  
 
 
Then, the scope of this multicomponent reaction between ethyl glyoxylate 1, ethyl 
phenylalaninate 2c and different maleimides 3 was next studied in toluene at -10 ºC with Ag2CO3 
as silver salt (Scheme 4). Maleimide 3b afforded the lowest enantioselectivity of this series (Table 
2, entry 1). N-Alkyl maleimides 3a, 3c, and 3d afforded good yields and high enantioselections for 
cycloadducts 4 (Table 2, entries 1, 3, and 4). N-Arylmaleimides such as N-phenylmaleimide (NPM) 











PhMe, -10 ºC, 1 d
Ag2CO3 (2.5% mol)
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Table 2. Multicomponent 1,3-DC of ethyl glyoxylate 1, phenylalanine ethyl ester 2, and 
maleimides 3. 
Ent. 3 R Product 4 Yield (%)a ee (%)b  
1 3a Me 4ca 94 90 (90) 
2 3b H 4cb 65 30 (30) 
3 3c Et 4cc 96 85 (88) 
4 3d PhCH2 4cd 95 77 (80) 
5 3e Ph 4ce 95 88 (90) 
6 3f 4-Br-C6H4 4cf 98 92 (92) 
a Isolated chemical yield obtained after column chromatography (silica gel). 




The general scope of this reaction was restricted to maleimides because the reaction depicted 
in Scheme 4 with other electrophilic alkenes gave low enantioselectivities. Thus, methyl and tert-
butyl acrylates gave good conversions (83, and 75% respectively) of the corresponding racemic 
cycloadduct. Methyl fumarate (70% conversion), and (E)-1,2-bis(phenylsulfonyl)ethylene (90% 
conversion) gave very low enantioselectivities (<10% ee), and β-nitrostyrene did not react at all. 
According to the physical and spectroscopic data reported for the racemic 1,3-DC we 
confirm that compounds 4 were isolated as only one diastereoisomer, derived from the generation 
of a W-dipole shape I (Figure 4) affording 2,5-cis-arrangement of both ester groups in 4. The 
absolute configuration of the final products was established following the usual trend of binap-
promoted enantioselective cycloadditions. (S)-Binap·AgX complexes induce 2S,3R,4S,5R absolute 
configuration in maleimide derived cycloadducts.11,14  
Based on our experience in this type of asynchronous concerted cycloaddition with 
maleimides employing stabilized 1,3-dipoles derived from arylideneglycinates or alaninates and 
considering the absence of non-linear effects, we performed a simple study of the lowest energy 
arrangement of chiral intermediate I.16 The presence of a monomeric (ligand-metal) structure A/B 
during computing series with a minimal energy value (108.3403 kcal/mol) was very satisfactory. 
From this saddle point intermediate, where the anion effect was not considered, it was possible to 
justify several experimental results. First, the high enantioselectivity observed just with the 
phenylalanine derivative can be originated, presumably, by a possible favorable π-stacking 
interaction between the phenyl ring of the amino ester and the phenyl group of a phosphorous 
atom.17 Distance of both aromatic rings (3.5-3.8 Å, better observed in view B) forces the chiral 
ligand to block one of the two faces of the dipole living accessible the opposite face. Second, the 
endo-approach of the maleimide by this face afforded the predicted the absolute configuration of 
compounds 4.  
 


























Figure 4. Proposed W-dipole shape I for the initial study. A and B are two different views of the 




A 1:1 mixture of (S)-binap and Ag2CO3 is the suitable catalyst (prepared in situ) for the 
multicomponent enantioselective 1,3-DC between the azomethine ylide, generated by ethyl 
glyoxylate and ethyl phenylalaninate, and maleimides. (S)-Binap·AgX complexes efficiency 
depends on the temperature due to the presence of several aggregates, which operate following 
different enantiodiscrimination patterns. The absence of an extra base and the highest 
enantioselections observed with a more basic counteranion of the silver salt suggest that this 
multicomponent sequence operates in the presence of a bifuntional catalyst activating and 
controlling the cycloaddition and promoting the deprotonation. The scope of the process is limited 
to ethyl phenylalaninate and maleimides. The origin of the high enantioselection resides in a π-




4. Experimental Part 
 
4.1. General information 
Melting points were determined with a Reichert Thermowar hot plate apparatus and are uncorrected. 
Only the structurally most important peaks of the IR spectra (recorded whit a FT-IR 4100LE (JASCO) 
(PIKE MIRacle ATR) are listed. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were obtained with a 
Bruker AC-300 by using CDCl3 as solvent and TMS as the internal standard, unless otherwise stated. Optical 
rotations were measured with a Perkin-Elmer 341polarimeter. HPLC analyses were performed with a 
JASCO-2000 series equipped with a chiral column (detailed for each compound in the main text) by using 
mixtures of n-hexane/isopropyl alcohol as the mobile phase at 25 ºC. Low-resolution electron impact (EI) 
mass spectra were obtained with a Shimadzu QP-5000 by injection or DIP, and high-resolution mass spectra 




were obtained with a Finnigan VG Platform or a Finnigan MAT 95S. Analytical TLC was performed on 
Schleicher & Schuell F1400/LS  254 silica gel plates and the spots were visualized under UV light (λ = 254 
nm). Merck silica gel 60 (0.040-0.063 mm) was used for flash chromatography. 
 
4.2. General procedure for the enantioselective 1,3-DC. 
In a 10 ml vial covered by aluminum foil, Ag2CO3 (6.9 mg, 0.025 mmol), (S)-binap 6 (31 mg, 0.050 
mmol) and toluene (3 mL) were added and the resulting mixture was stirred at room temperature for 1 h. The 
mixture was cooled at -10 ºC and the amino ester 2c (193 mg, 1 mmol), the corresponding maleimide 3 (1 
mmol), and ethyl glyoxylate 1 (ca.50% solution in toluene, 102 μL, 1.2 mmol) were slowly added in this 
order. The reaction was stirred 1 d at -10 ºC and the crude was analyzed by 1H NMR spectroscopy to 




dicarboxylate (4ca).  
[α ]D20= -23.8 (c 1, CHCl3), 90% ee from HPLC (Chiralpak AD-H, 90:10, n-hexane:isopropyl alcohol, 1 
mL/min, tmin 46.5 min, tmaj 50.0 min); IR (neat) νmax 3030, 2982, 2936, 1779, 1734, 1699 cm-1; 1H NMR δH: 
1.32, 1.34 (2t, J = 7.2 Hz, 3H, CO2CH2CH3), 2.88, 3.30 (2d, J = 13.8 Hz, 2H, CH2Ph), 2.92 (s, 3H, NCH3), 
3.38 [d, J = 8.0 Hz, 1H, CHC(CO2Et)Bn],  3.55 [deform. dd, J = 8.4, 8.0 Hz, 1H, CHCH(CO2Et)NH], 4.09 
[d, J = 8.4, Hz, 1H, CH(CO2Et)NH], 4.24 (q, J = 7.2 Hz, 2H, CO2CH2CH3 ), 4.26 (q, J = 7.2 Hz, 2H, 
CO2CH2CH3), 7.23-7.27 (m, 5H, ArH), NH nd; 13C NMR δC: 14.0 (2xCO2CH2CH3), 25.4 (NCH3), 42.2 
(CH2Ar), 50.4 [CHCH(CO2Et)NH], 56.6 [CHC(CO2Et)Bn], 62.0 [CH(CO2Et)NH], 62.1, 62.3 
(2xCO2CH2CH3), 73.6 [C(CO2Et)Bn], 127.2, 128.3, 130.4, 135.7 (ArC), 169.6, 170.1 (2xCO2), 175.0, 
175.1 (2xCON); MS (EI-GC) m/z: 388 (M++1, <1%), 315 (13), 298 (14), 297 (100), 223 (11), 166 (45), 94 
(11), 91 (17); HRMS calculated for C20H24N2O6: 388.1634, found: 388.1631.  
 
4.4. Diethyl (1S,3R,3aS,6aR)-1-benzyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1,3-dicarboxylate 
(4cb).  
[α ]D20= -12.8 (c 1, CHCl3), 30% ee from HPLC (Chiralpak OD-H, 90:10, n-hexane:isopropyl alcohol, 1 
mL/min, , tmaj 36.7 min, tmin 73.5 min); IR (neat) νmax 3220, 1731, 1700 cm-1; 1H NMR δH: 1.28–1.34 (m, 
6H, 2xCO2CH2CH3), 2.88, 3.33 (2xd, J = 13.8 Hz, 2H, CH2Ph), 3.50 (br. s, 1H, NH), 3.42 [d, J = 7.8 Hz, 
1H, CHC(CO2Et)Bn], 3.58 [deform. dd, J = 8.0, 7.8 Hz, 1H, CHCH(CO2Et)NH], 4.11–4.18 [m, 1H, 
CH(CO2Et)NH], 4.20–4.28 [m, 4H, 2xCO2CH2CH3], 7.27–7.29 (m, 6H, ArH and NH); 13C NMR δC: 14.1, 
14.2 (2xCO2CH2CH3), 42.2 (CH2Ph), 51.5 [CHCH(CO2Et)NH], 57.7 [CHCH(CO2Et)NH], 62.2, 62.4 
(2xCO2CH2CH3), 62.5 [CH(CO2Et)NH], 73.7 [CBn(CO2Et)NH], 123.0, 128.5, 130.5, 135.7 (ArC), 169.6, 
170.1 (2xCO2), 175.0, 174.9 (2xCON); MS (EI-GC) m/z: 374 (M+, 11%), 155 (15), 94 (13), 91 (100); 
HRMS calculated for C19H22N2O6: 374.1478, found: 374.1489. 
 
4.5. Diethyl (1S,3R,3aS,6aR)-1-benzyl-5-ethyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1,3-
dicarboxylate (4cc).  
[�]D20= -17.7 (c 1, CHCl3), 88% ee from HPLC (Chiralpak OD-H, 90:10, n-hexane:isopropyl alcohol, 1 
mL/min, tmin 14.7 min, tmaj 33.4 min); IR (neat) νmax 3002, 2985, 2930, 1725, 1715, 1700 cm-1; 1H NMR δH: 
1.12 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.35, 1.37 (2t, J = 7.2 Hz, 6H, 2xCO2CH2CH3), 2.92, 3.34 (2d, J = 13.9 
Hz, 2H, CH2Ph), 3.39 [d, J = 7.7 Hz, 1H, CHC(CO2Et)Bn],  3.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 3.55 
[deform. dd, J = 8.6, 7.7 Hz, 1H, CHCH(CO2Et)NH], 4.10 [d, J = 8.6, Hz, 1H, CH(CO2Et)NH], 4.24-4.32 
(m, 4H, 2xCO2CH2CH3), 7.23-7.27 (m, 5H, ArH), NH nd; 13C NMR δC: 13.1, 14.1, 14.2 (3xCO2CH2CH3), 
34.4 (NCH2CH3), 42.3 (CH2Ar), 50.3 [CHCH(CO2Et)NH], 56.6 [CHC(CO2Et)Bn], 62.0 [CH(CO2Et)NH], 
62.2, 62.4 (2xCO2CH2CH3),  73.8 [C(CO2Et)Bn], 127.3, 128.3, 130.5, 135.8 (ArC), 169.6, 170.1 (2xCO2), 
174.8, 174.9 (2xCON); MS (EI-GC) m/z: 402 (M++1, <1%), 329 (10), 315 (10), 298 (15), 297 (100), 222 
(10), 166 (50), 94 (11), 91 (18); HRMS calculated for C21H26N2O6: 402.1791, found: 402.1789. 
 




4.6. Diethyl (1S,3R,3aS,6aR)-1,5-dibenzyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1,3-dicarboxylate 
(4cd).  
[α ]D20= -36.9 (c 1, CHCl3), 80% ee from HPLC (Chiralpak AD-H, 90:10, n-hexane:isopropyl alcohol, 1 
mL/min, tmaj 23.9 min, tmin 42.7 min); IR (neat) νmax 3030, 2989, 1741, 1719, 1699 cm-1; 1H NMR δH: 1.23 
(t, J = 7.2 Hz, 3H, CO2CH2CH3), 1.28 (t, J = 7.2 Hz, 3H, CO2CH2CH3), 2.89, 3.31 (2d, J = 13.9 Hz, 2H, 
CH2Ph), 3.38 [d, J = 7.8 Hz, 1H, CHC(CO2Et)Bn], 3.55 [deform. dd, J = 7.8, 7.8 Hz, 1H, 
CHCH(CO2Et)NH], 4.03–4.27 (m, 5H, 2xCO2CH2CH3 and CH(CO2Et)NH], 4.54, 4.60 (d, J = 14.3 Hz, 2H, 
CH2Ph), 7.20–7.35 (m, 10H, ArH), NH nd; 13C NMR δC: 14.0, 14.1 (2xCO2CH2CH3), 42.2, 43.0 
(2xCH2Ph), 50.4 [CHCH(CO2Et)NH], 56.6 [CHCH(CO2Et)NH], 61.9, 62.1 (2xCO2CH2CH3), 62.3 
[CH(CO2Et)NH], 73.7 [CBn(CO2Et)NH], 127.2, 128.0, 128.3, 128.6, 128.7, 130.5, 135.2, 135.8 (ArC), 
169.4, 169.9 (2xCO2CH2CH3), 174.6, 174.7 (2xCON); MS (EI-GC) m/z: 464 (M++1, <1%), 391 (14), 374 
(22), 373 (100), 166 (22), 91 (73); HRMS calculated for C26H28N2O6 – C7H7: 373.1400, found: 373.1401. 
 
4.7. Diethyl (1S,3R,3aS,6aR)-1-benzyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1,3-
dicarboxylate (4cd).  
[α ]D20= -28.0 (c 1, CHCl3), 90% ee from HPLC (Chiralpak AD-H, 90:10, n-hexane:isopropyl alcohol, 1 
mL/min, tmaj 42.0 min, tmin 51.1 min); IR (neat) νmax 2979, 2937, 1729, 1714 cm-1; 1H NMR δH: 1.25–1.30 
(m, 6H, 2xCO2CH2CH3), 2.96, 3.36 (2xd, J = 13.9 Hz, 2H, CH2Ph), 3.51 (s, 1H, NH), 3.55 [d, J = 7.8 Hz, 
1H, CHC(CO2Et)Bn], 3.73 [deform. dd, J = 7.8, 7.8 Hz, 1H, CHCH(CO2Et)NH], 4.15–4.30 [m, 5H, 
2xCO2CH2CH3 and CH(CO2Et)NH], 7.15–7.49 (m, 10H, ArH); 13C NMR δC: 13.9, 14.0 (2xCO2CH2CH3), 
42.3 (CH2Ph), 50.4 [CHCH(CO2Et)NH], 56.6 [CHCH(CO2Et)NH], 62.1, 62.2 (2xCO2CH2CH3), 62.3 
[CH(CO2Et)NH], 74.1 [CBn(CO2Et)NH], 126.6, 127.2, 128.0, 128.2, 128.9, 129.2, 130.4, 135.6 (ArC), 
169.7, 170.1 (2xCO2), 174.0, 174.2 (2xCON); MS (EI-GC) m/z: 450 (M++1, <1%), 377 (14), 360 (22), 359 




1,3-dicarboxylate (4cf).  
[α ]D20= -32.6 (c 1, CHCl3), 92% ee from HPLC (Chiralpak OD-H, 80:20, n-hexane:isopropyl alcohol, 1 
mL/min, tmaj 25.3 min, tmin 30.0 min); IR (neat) νmax 2979, 1731, 1700 cm-1; 1H NMR δH: 1.27–1.33 (m, 6H, 
2xCO2CH2CH3), 2.96, 3.35 (2xd, J = 13.9 Hz, 2H, CH2Ph), 3.51 (br. s, 1H, NH), 3.56 [d, J = 7.8 Hz, 1H, 
CHC(CO2Et)Bn], 3.67 [deform. dd, J = 8.0, 7.8 Hz, 1H, CHCH(CO2Et)NH], 4.11–4.18 [m, 1H, 
CH(CO2Et)NH], 4.20–4.28 [m, 4H, 2xCO2CH2CH3], 7.09 (d, J = 8.6 Hz, 2H, ArH), 7.27–7.29 (m, 5H, 
ArH), 7.55 (d, J = 8.6 Hz, 2H, ArH); 13C NMR δC: 14.1, 14.2 (2xCO2CH2CH3), 42.5 (CH2Ph), 50.6 
[CHCH(CO2Et)NH], 56.7 [CHCH(CO2Et)NH], 62.4, 62.5 (2xCO2CH2CH3), 62.6 [CH(CO2Et)NH], 74.4 
[CBn(CO2Et)NH], 123.0, 127.4, 128.3, 128.4, 128.5, 130.5, 132.6, 135.7 (ArC), 169.9, 170.3 (2xCO2), 
173.9, 174.0 (2xCON); MS (EI-GC) m/z: 528, 530 (M++2, <1%), 451 (10), 374 (15), 361 (21), 360 (10), 359 
(100), 207 (48), 166 (31), 155 (10), 119 (10), 94 (13), 91 (45); HRMS calculated for C25H25BrN2O6: 
528.0896, found: 528.0891. 
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